NextCure (NXTC) Presents At Life Sciences Conference - Slideshow

✓ 5 dose cohorts: 0.5 – 20 mg/kg · Phase 1b monotherapy dose expansion initiated 19 Killing leukemic stem cells while preserving healthy immune cells 20 LAIR-1 Antibody 11B3* Reduces Tumor Burden in Murine Leukemia Model *11B3: NC525 Murine Parent 02W · Bone marrow blast clearance PERIPHERAL BLOOD 23 ✓ Submitted & cleared IND · Phase 1 monotherapy dose escalation & safety · Biomarkers Powerful, Proven, and Productive Discovery Engine Fuels Our Pipeline Growth · Membrane proteins · Soluble proteins CELL TYPE ...